Year All202420232022202120202019201820172016201520142013 March 18, 2024 Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer Read more March 4, 2024 Arvinas to Participate in Upcoming Investor Conferences Read more February 27, 2024 Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Read more February 20, 2024 Arvinas Announces Chief Financial Officer Transition Read more February 20, 2024 Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease Read more February 6, 2024 Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer Read more February 1, 2024 Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference Read more January 16, 2024 Arvinas Appoints Jared Freedberg as General Counsel Read more
February 27, 2024 Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Read more
February 20, 2024 Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease Read more
February 6, 2024 Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer Read more
